Citadel Advisors’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$101M Buy
1,611,900
+951,300
+144% +$76.1M 0.02% 801
2025
Q4
$63M Buy
660,600
+59,200
+10% +$5.8M 0.01% 1216
2025
Q3
$58.7M Sell
601,400
-181,000
-23% -$18.7M 0.01% 1230
2025
Q2
$84M Sell
782,400
-434,400
-36% -$44M 0.01% 881
2025
Q1
$123M Buy
1,216,800
+572,400
+89% +$57.6M 0.02% 579
2024
Q4
$57.6M Buy
644,400
+52,800
+9% +$4.65M 0.01% 1156
2024
Q3
$49.6M Sell
591,600
-79,400
-12% -$6.26M 0.01% 1218
2024
Q2
$51.7M Sell
671,000
-107,800
-14% -$7.89M 0.01% 1121
2024
Q1
$53.3M Sell
778,800
-43,000
-5% -$2.76M 0.01% 1158
2023
Q4
$47.5M Buy
821,800
+121,600
+17% +$6.49M 0.01% 1234
2023
Q3
$37M Buy
700,200
+291,900
+71% +$15.3M 0.01% 1324
2023
Q2
$22.1M Sell
408,300
-210,900
-34% -$11M ﹤0.01% 1773
2023
Q1
$31M Buy
619,200
+62,500
+11% +$2.95M 0.01% 1509
2022
Q4
$25.8M Buy
556,700
+86,100
+18% +$3.73M 0.01% 1697
2022
Q3
$18.2M Sell
470,600
-97,000
-17% -$3.89M ﹤0.01% 1977
2022
Q2
$21.2M Buy
567,600
+130,500
+30% +$5.31M 0.01% 1795
2022
Q1
$19.4M Sell
437,100
-325,800
-43% -$14.1M ﹤0.01% 2019
2021
Q4
$32.4M Sell
762,900
-359,100
-32% -$15.1M 0.01% 1536
2021
Q3
$48.7M Sell
1,122,000
-526,700
-32% -$23.3M 0.01% 1143
2021
Q2
$70.5M Buy
1,648,700
+474,200
+40% +$20M 0.02% 885
2021
Q1
$45.4M Buy
1,174,500
+409,900
+54% +$15.5M 0.01% 1125
2020
Q4
$27.5M Buy
764,600
+290,300
+61% +$10.5M 0.01% 1479
2020
Q3
$18.1M Sell
474,300
-63,200
-12% -$2.44M 0.01% 1663
2020
Q2
$18.9M Sell
537,500
-238,600
-31% -$8.59M 0.01% 1555
2020
Q1
$25.3M Buy
776,100
+430,500
+125% +$16.8M 0.01% 1054
2019
Q4
$15.6M Sell
345,600
-478,900
-58% -$20M 0.01% 1721
2019
Q3
$33.5M Sell
824,500
-171,600
-17% -$7.27M 0.02% 1038
2019
Q2
$42.8M Buy
996,100
+668,900
+204% +$25.7M 0.02% 835
2019
Q1
$12.6M Sell
327,200
-1,100
-0.3% -$42K 0.01% 1808
2018
Q4
$11.6M Buy
328,300
+86,800
+36% +$3.15M 0.01% 1731
2018
Q3
$9.3M Sell
241,500
-123,300
-34% -$4.31M ﹤0.01% 2187
2018
Q2
$11.9M Buy
364,800
+220,200
+152% +$6.64M 0.01% 1768
2018
Q1
$3.95M Buy
144,600
+47,500
+49% +$1.29M ﹤0.01% 2742
2017
Q4
$2.41M Sell
97,100
-85,200
-47% -$2.35M ﹤0.01% 3375
2017
Q3
$5.32M Buy
182,300
+6,800
+4% +$188K ﹤0.01% 2248
2017
Q2
$4.87M Buy
175,500
+3,200
+2% +$84.9K ﹤0.01% 2162
2017
Q1
$4.29M Sell
172,300
-43,800
-20% -$1.07M ﹤0.01% 2197
2016
Q4
$4.67M Sell
216,100
-142,500
-40% -$3.11M ﹤0.01% 2075
2016
Q3
$8.54M Buy
358,600
+144,400
+67% +$3.44M 0.01% 1506
2016
Q2
$5.01M Sell
214,200
-61,800
-22% -$1.34M 0.01% 1827
2016
Q1
$5.19M Buy
276,000
+113,000
+69% +$1.98M 0.01% 1735
2015
Q4
$3.01M Buy
163,000
+48,800
+43% +$874K ﹤0.01% 2324
2015
Q3
$1.87M Sell
114,200
-3,200
-3% -$54.7K ﹤0.01% 3026
2015
Q2
$2.08M Sell
117,400
-104,200
-47% -$1.86M ﹤0.01% 3021
2015
Q1
$3.93M Sell
221,600
-7,500
-3% -$119K ﹤0.01% 2289
2014
Q4
$3.04M Buy
229,100
+172,500
+305% +$2.21M ﹤0.01% 2473
2014
Q3
$668K Buy
56,600
+16,600
+42% +$209K ﹤0.01% 4230
2014
Q2
$511K Sell
40,000
-155,400
-80% -$2.02M ﹤0.01% 4353
2014
Q1
$2.64M Buy
195,400
+69,000
+55% +$906K ﹤0.01% 2365
2013
Q4
$1.52M Sell
126,400
-234,700
-65% -$2.77M ﹤0.01% 2807
2013
Q3
$4.24M Buy
361,100
+55,800
+18% +$604K 0.01% 1701
2013
Q2
$2.83M Buy
+305,300
New +$2.59M ﹤0.01% 2117

Other funds holding BSX

Citadel Advisors's BSX Position: Q1 2026 in Review

Citadel Advisors reduced its Boston Scientific (BSX) stake by 12% in Q1 2026, selling an estimated $44.7M and leaving 4,217,314 shares worth $265M. The position accounts for 0.04% of the portfolio, ranked #342.

Citadel Advisors first reported a position in BSX in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.12B in Q3 2023. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Citadel Advisors held 4,217,314 shares of Boston Scientific worth $265M as of Q1 2026.
  • Citadel Advisors sold 558,304 Boston Scientific shares in Q1 2026, an estimated $44.7M.
  • Boston Scientific made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #342 holding.
  • Citadel Advisors first reported a position in Boston Scientific in Q2 2013 and has held it in 51 quarters since.
  • Citadel Advisors's Boston Scientific position peaked at $1.12B in Q3 2023.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.